Akèy › Metiyè › Chemists › Durham, NC
Chemists nan Durham, NC: Salè H-1B
82 aplikasyon kondisyon travay pou okipasyon sa a ak yon sit travay nan Durham, NC. Salè baz medyàn ofri $90,000; mwatye mitan $75,476–$104,686.
Demann (LCA)82
Salè medyan ofri$90,000
Mwatye salè yo$75,476–$104,686
10yèm–90yèm pousantaj$62,000–$121,080
Pa nivo salè
| Nivo revni | Salè medyan |
|---|---|
| Nivo I (antre) | $62,000 |
| Nivo II (kalifye) | $80,000 |
| Nivo III (eksperyans) | $92,603 |
| Nivo IV (plen kompetans) | $118,450 |
Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.
Anplwayè yo
| Anplwayè | LCA | Salè medyan |
|---|---|---|
| Tergus Pharma, LLC | 13 | $115,000 |
| Duke University | 11 | $62,000 |
| Research Triangle Institute (U.S.) | 9 | $75,405 |
| KBI Biopharma, Inc. | 8 | $99,000 |
| Aurolife Pharma LLC | 6 | $86,500 |
| Research Triangle Institute | 5 | $91,560 |
| MedPharm Manufacturing Services LLC | 5 | $104,564 |
| Alcami Carolinas Corporation | 4 | $102,731 |
| Novartis Gene Therapies, Inc. | 3 | $75,691 |
| Symmetry BioSciences Inc. | 3 | $80,000 |
| Ten63 Therapeutics Inc. | 3 | $150,000 |
| Aurobindo Pharma USA, Inc. | 2 | $86,103 |
| Avista Pharma Solutions, Inc. | 2 | $77,251 |
| Solve Therapeutics, Inc. | 2 | $84,000 |
| Novo Nordisk Pharmaceutical Industries, LP | 2 | $105,000 |
| Alpha Nano Tech LLC | 1 | $58,510 |
| Fortrea Inc. | 1 | $104,915 |
| Syngenta Crop Protection LLC | 1 | $92,206 |
| Splint Pharma LLC | 1 | — |
Tit travay
- Postdoctoral Associate8
- Manager Analytical Chemist4
- Chemist 24
- Research Associate3
- Senior Scientific Engineer3
- Scientist III, Analytical Chemist2
- Scientist II, Analytical R&D2
- Senior Scientist2
- Research Chemist2
- Senior Analyst, Analytical Lab2
- Research Chemist 22
- Catalyst Research Scientist2
- Sr. Scientist II (ARD)2
- Radiopharmaceutical Scientist2
- Senior Analyst, Quality Control1
Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).